Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)
By ryandahlhauser ‐ September 7, 2023
This is an update to the 2016 statement by ACMG (American College of Medical Genetics), where patients should be made aware of NIPS (Noninvasive prenatal screening). Now, due to high strength and quality of evidence, NIPS is strongly recommended over traditional screening methods for trisomies 21, 18, and 13 in singleton and twin gestations. It should also be offered in terms of sex chromosomal aneuploidy and 22q11.2 deletion. However, there is insufficient evidence for other trisomies or deletions at this time, but more research is being done. NIPS as a screening method and not absolute should still be stressed to patients, in addition to proper pre and post test counseling.